...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>International heart journal >Efficacy of nifekalant hydrochloride in the treatment of fatal ventricular arrhythmia in patients with ischemic heart disease.
【24h】

Efficacy of nifekalant hydrochloride in the treatment of fatal ventricular arrhythmia in patients with ischemic heart disease.

机译：盐酸奈非卡那特治疗缺血性心脏病患者致命性室性心律失常的疗效。

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Ventricular tachycardia (VT), which causes hemodynamic instability, and ventricular fibrillation (VF) sometimes occur in patients with severe underlying cardiovascular disease such as myocardial ischemia or infarction, and are associated with high mortality. This report presents the efficacy of nifekalant hydrochloride (nifekalant), a pure class III antiarrhythmic agent, in treating life-threatening ventricular arrhythmia in such patients. From June 2000, when nifekalant became commercially available in Japan, to May 2003, 30 ischemic heart disease (IHD) patients with VT/VF resistant to direct-current (DC) countershock received nifekalant in our hospital. These 30 patients served as the nifekalant group in this study. As a control group, we also included 33 IHD patients with VT/VF that had been resistant to DC countershock upon or during hospitalization between January 1996 and May 2000 before nifekalant became commercially available. No significant differences were observed in patient background factors and treatments between the two groups. The rates of death within 48 hours of occurrence of VT/VF were significantly lower in the nifekalant group (7%, 2/30) than in the control group (27%, 9/33; P < 0.03). The rates of cardiac death during hospitalization were also significantly lower in the nifekalant group (40%, 12/30) than in the control group (67%, 22/33; P < 0.03). The rates of survival until hospital discharge were significantly higher in the nifekalant group (57%, 17/30) than in the control group (30%, 10/33; P < 0.03). Multivariate analysis of all 63 patients revealed nifekalant administration was the factor that significantly improved the mortality (odds ratio for cardiac death, 0.26; 95% confidence interval (CI), 0.07 to 0.95; P = 0.041). Nifekalant improves the prognosis for life-threatening ventricular arrhythmia in IHD patients.
机译：引起血液动力学不稳定的室性心动过速（VT）和心室纤颤（VF）有时会发生在患有严重的基础性心血管疾病（例如心肌缺血或梗塞）的患者中，并伴有高死亡率。本报告介绍了盐酸尼非卡兰（nifekalant）（一种纯净的III类抗心律不齐药物）在此类患者中危及生命的心律失常的疗效。从2000年6月nifekalant在日本市售开始，到2003年5月，我院接受30例对直流电（DC）抗休克的VT / VF缺血性心脏病（IHD）患者的治疗。这30例患者在本研究中作为硝苯甲酸盐治疗组。作为对照组，我们还包括了33例IHD VT / VF患者，这些患者在1996年1月至2000年5月尼菲卡仑市售前住院期间或住院期间对DC反电击耐药。两组之间的患者背景因素和治疗均未观察到显着差异。 Nifekalant组的VT / VF发生48小时内的死亡率显着低于对照组（27％，9/33; P <0.03）（7％，2/30）。 Nifekalant组的住院期间心源性死亡发生率（40％，12/30）也显着低于对照组（67％，22/33; P <0.03）。硝苯丙​​酸组直至出院的存活率（57％，17/30）显着高于对照组（30％，10/33; P <0.03）。对所有63例患者的多变量分析显示，硝苯丙酸治疗是显着改善死亡率的因素（心源性死亡的几率为0.26; 95％的置信区间（CI）为0.07至0.95; P = 0.041）。尼非卡兰可改善IHD患者危及生命的心律失常的预后。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号